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Abstract: Adenovirus is a robust vector for therapeutic applications, but its use is limited by our understanding of its 
complex in vivo pharmacology. In this review we describe the necessity of identifying its natural, widespread, and multi-
faceted interactions with the host since this information will be crucial for efficiently redirecting virus into target cells. In 
the rational design of vectors, the notion of overcoming a sequence of viral “sinks” must be combined with re-targeting to 
target populations with capsid as well as shielding the vectors from pre-existing or toxic immune responses. It must also 
be noted that most known adenoviral pharmacology is deduced from the most commonly used serotypes, Ad5 and Ad2. 
However, these serotypes may not represent all adenoviruses, and may not even represent the most useful vectors for all 
purposes. Chimeras between Ad serotypes may become useful in engineering vectors that can selectively evade substan-
tial viral traps, such as Kupffer cells, while retaining the robust qualities of Ad5. Similarly, vectorizing other Ad serotypes 
may become useful in avoiding immunity against Ad5 altogether. Taken together, this research on basic adenovirus biol-
ogy will be necessary in developing vectors that interact more strategically with the host for the most optimal therapeutic 
effect.  
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INTRODUCTION 
  Adenoviruses (Ads) are icosahedral non-enveloped DNA 
viruses with diameters approximately 90 to 100 nm (Fig. 1). 
Ads were first isolated from human adenoids in 1953 and 
since then, bovine, ovine, murine, canine, equine, porcine, 
and caprine specific strains have also been identified [1]. 
With over 50 currently recognized human serotypes, Ads are 
widely present in human populations (Table 1). These vi-
ruses are typically associated with mild disease, however 
more severe complications may occur in infants or in im-
munocompromised patients. Most Ad serotypes manifest 
with mild respiratory symptoms, although others have vari-
ous pathologies like acute respiratory disease (Ad3, 4, 7, 14, 
21), keratoconjunctivitis (Ad8, 9, 10, 19), gasteroenteritis 
(Ad40, 41), and even obesity (Ad36) [2-4]. 
  Adenoviruses have several features that make them in-
herently useful as oncolytic, vaccine, or gene therapy vec-
tors. For instance, they are non-enveloped viruses and are 
therefore sufficiently stable for packaging as lyophilized 
preparations in vials or capsules, even without a cold chain. 
They mediate high transduction efficiency in non-dividing 
(i.e. most human somatic cells) and dividing cells (i.e. trans-
formed cells) and can generate 10
4 virus particles (vp) per 
infected cell. This supports large-scale preparations of 10
13 
vp from 10
9 cells.  
  Ad genomes range from ~36-40 kilobase pairs (kb) in 
length and can carry large transgenes up to this size. Their  
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DNA genome and high fidelity DNA polymerase confers 
relative genomic stability in comparison to RNA viruses. 
Furthermore, unlike retroviruses, Ad genomes are non-
integrating. While this poses minimal risk for insertional 
mutagenesis [5] these vectors are comparatively ineffective 
for the genetic modification of dividing cells since cell divi-
sion will result in loss of the transgene [6, 7]. On the other 
hand, Ad genomes can persist for years in non-dividing cells 
provided that an immune response is not produced against 
Ad or the transgene product. 
  When applied as a gene therapy agent, intravenous deliv-
ery of Ad5 into mice produces supraphysiologic levels of its 
transgene. For example, in vivo genetic modification of mice 
with Ad5 resulted in 6 mg/ml of 1-antitrypsin in the circu-
lation; these are levels at which the transgene became the 
second most abundant protein in the blood [8]. In other 
words, when Ad has been applied as a gene-based vaccine it 
is one of the most robust platforms.  
  While Ads are potent in vivo gene delivery platforms, 
they are also robust at generating immune responses. For 
example, a head to head comparison with vaccinia virus vec-
tors or plasmid DNA vaccines in non-human primates dem-
onstrated that Ad mediated the most robust immune re-
sponses [9]. This effect is fortuitous for vaccine purposes, 
but is problematic for gene therapy approaches. For instance, 
pre-existing immunity against the virus or the transgene pro-
tein reduces the persistence of genetic correction [5-7, 10, 11].  
  This review is an update and expansion of a previous 
review by our laboratory that was published in 2007 ([12] 
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This earlier review provided a comprehensive discussion of 
Ad protein composition, structure, and life cycle. It also in-
tegrated applications of basic Ad biology in terms of vector 
targeting and strategies for vector improvement, such mo-
lecular linkers, genetic, and chemical modifications with a 
particular emphasis on modification of the Ad fiber protein 
for targeting efforts. The 2007 review was also Ad5-centric, 
focusing on the most utilized adenoviral serotype for gene 
therapy. 
Table  1.  Classification of Human Adenoviral Serotypes [37, 
195] 
Species Serotype 
A  12, 18, 31 
B  3, 7, 11, 14, 16, 21, 34, 35, 50, 55 
C  1, 2, 5, 6 
D  8, 9, 10, 13, 15, 17, 19, 20, 22, 23, 24, 25, 26, 27, 
28, 29, 30, 32, 33, 36, 37, 38, 39, 42, 43, 44, 45, 46, 
47, 48, 49, 51, 53, 54 
E 4 
F 40,  41 
G 52 
 
  In this update, we have incorporated recent information 
of Ad vector biology and targeting as it stands in 2011. In 
particular, we address the growing understanding of in vivo 
virus pharmacology rather than in vitro virus-cell biology. 
We discuss the biology of Ad5 and other Ad serotypes in 
vivo with particular emphasis on the known and speculated 
pharmacology “sinks” for these viruses that affect their use 
for systemic or targeted therapy. This review will also dis-
cuss recent observations regarding the role of the Ad hexon 
protein on in vivo (but not in vitro) virus tropism and how 
recent engineering efforts have been directed more at adeno-
virus “detargeting” than adenovirus “retargeting”. With de-
targeting of significant pharmacologic sinks nearly at hand, 
the field will now likely be able to apply the retargeting 
strategies that appeared promising in vitro, but that have his-
torically failed in vivo. 
ADENOVIRUS SPECIES AND SEROTYPES 
  Adenoviruses were originally defined by a number of 
bioassays including cross-susceptibility to neutralizing anti-
bodies and subsequent categorization into serotypes. With 
the advent of DNA sequencing, newer viruses are now being 
characterized by genotype and phylogenetic comparisons to 
other Ad genomes (Fig. 2 and see [13] for an excellent re-
view). Current convention is to describe distinct Ads as new 
serotypes although they are now typically classified by geno-
typing.  
  Based on serotyping, related human and non-human Ads 
were formerly referred to as subgroups. With the advent of 
more sequence data, this designation has been revised to 
describe the different groups as species. There are currently 
55 human adenovirus serotypes that distribute into seven 
species from A to G (Table 1) [14]. As of this writing only 
34 full genome sequences are available for full genome 
comparison (Fig. 2). The vast majority of data on the biology 
of Ads has been garnered using species C adenoviruses Ad2 
and Ad5 in cell culture. Therefore, most knowledge of virus-
cell interactions is based largely on two out of now 55 hu-
man Ad serotypes. While many lessons learned with Ad2 
and Ad5 will still apply to other Ads, many others do not 
apply. 
  More recently, a variety of groups have delved into the 
biologies of other human and non-human Ads in the quest 
for new functionalities or to evade anti-Ad5 immunity in 
patients [15-23]. In this review, we describe some aspects of 
novel Ad biologies that vary between species and serotypes. 
 
 
 
 
 
 
 
Fig. (1). Schematic of Ad capsid structure. (a) Cryo-electron micrograph reconstruction of the Ad5 capsid. The dotted triangle overlays 
one of the 20 facets of the icosahedron. (b) Diagram of the adenoviral capsid showing a "group of nine" hexon trimers, penton bases, and 
fiber n-terminus that is observed in cryo-EM.  (c) Addition of flexible fiber structures to B that are not observed in cryo-EM. 
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For additional information, see several reviews on different 
Ad serotypes [10, 24-26]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Phylogenetic Tree of Human Adenoviruses.  Full ge-
nome comparison of 34 completed Ad sequences groups viruses 
with species grouping according to genetic similarity. 
NATURAL CELL BINDING AND ENTRY BY ADE-
NOVIRUSES 
  In vitro, adenoviruses infect permissive host cells rapidly 
and efficiently. Typical time from infection to the production 
of new virions ranges from 14 to 19 hours depending on se-
rotype [27]. Initial interactions with cellular receptors could 
theoretically be mediated by any surface exposed protein on 
the virus (Table 2 and see [12] http://www.ncbi.nlm.nih.gov/ 
pmc/articles/PMC2244792/) for background on virus struc-
ture/function). Early work in Ad interactions identified a 
subset of proteins that interact with receptors in vitro (fiber, 
penton base) and in vivo fiber, penton base, hexon, (Fig. 1). 
As more of these interactions are revealed exposed, more 
proteins will likely be found to interact directly or indirectly 
with receptors and proteins under certain circumstances (see 
interactions of hexon with blood factors below).  
Adenovirus Major Capsid Proteins 
  There are three major capsid proteins on adenoviruses: 
fiber, penton base, and hexon (Fig. 1). There are 36 mono-
mers of fiber, 60 monomers of penton base, and 720 mono-
mers of hexon on each Ad virion. There is good evidence 
that the fiber and penton base proteins of many Ad serotypes 
interact directly with cellular receptors. In contrast, there is 
little evidence showing that hexons display a ligand for cel-
lular receptors. The massive number of hexons per virion 
certainly has the possibility of mediating avidity interactions 
via multivalent charge interactions. However, a high affinity 
evolved ligand has not been associated with Ad5 or any Ad 
hexon to date.  
  Under the simplest circumstances on permissive cells, the 
Ad fiber protein acts as the primary high affinity attachment 
protein for the virus in vitro,  provided its receptor is ex-
pressed on cells. Three fiber monomers trimerize to form an 
antenna-like structure located at each vertex of the icosahe-
dral capsid (Fig. 1C). The tail domain of the trimer attaches 
directly to penton; the shaft length is determined by multiple 
amino acid repeats; the knob domain confers specificity to 
cellular receptors. 
  Although fibers across the seven human Ad species have 
the same basic structure, their amino acid sequences and 
shaft lengths vary considerably. Prototype Ad5 fiber binds to 
CAR, the coxsackie and adenovirus receptor (reviewed in 
[12, 25]). Viruses from other species can bind to CAR, 
CD46, sialic acid, desmoglein-2, and perhaps other receptors 
[25, 28]. 
  In vitro, Ad5 binds CAR and also binds to cellular v 
integrins [29]. Ad5 binds CAR with 15 nM affinity, whereas 
penton base engages integrins with 10-fold lower affinity 
[29]. Because of this affinity difference, species C viruses 
have been shown to first engage CAR and then rapidly tran-
sition to binding and entry via interaction with integrins [30]. 
This dual receptor utilization is made possible by the length 
and flexibility of the Ad5 fiber (Fig. 1C). Ad5 has one of the 
longest fiber proteins with 21 -spiral repeats in its shaft [31] 
(sometimes referred to as having 22 repeats [25]).  
  Exactly how Ad5 could transition from binding CAR to 
binding integrins was unclear until it was realized that its 
fiber is able to bend due to a flexible lysine-lysine-threonine-
lysine (KKTK) motif at repeat three in its shaft ([32] and Fig 
1C). This flexibility can be appreciated in cryo-electron mi-
croscopic (cryo-EM) reconstructions of Ad5 for although 
they are one-third the diameter of the icosahedron, the 
twelve 35 nm fibers are not observed. Instead, only a stump 
of the fiber can be seen (Fig. 1A) [33, 34]. This loss of fiber 
electron density results from the computational assembly and 
integration of hundreds of the images of individual Ad viri-
ons during cryo-EM image reconstruction. Proteins like 
hexon, that are fixed in space on the virion resolve into struc-
tures (Fig. 1A). If the proteins are flexible, then they will be 
in a different orientation with respect to the virion. When this 
is averaged between hundreds of virions, these mobile Ad5 
fiber proteins disappear. In contrast, when short-shafted fi-
bers that lack this flexible KKTK domain are imaged, their 
shafts can be observed [35]. Fibers also have an additional 
flexibility motif between the fiber shaft and knob domain 
([31] and Fig. 1C). This can be inferred in cryo-EM using 
short-shafted Ad35 fiber, since its shaft is observed, but its 
knob is not [35].  
  This flexibility allows the long-limbed Ad5 to undergo 
"virus yoga" [32] wherein the fiber knob binds CAR and 
then the shaft flexes to allow an arginine-glycine-aspartic 
acid (RGD) motif on penton to bind to v1, v3, v5 or 
31 integrins on the cell surface [29]. Binding of RGD to 
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Table 2.  Summary of Encapsidated Proteins in Adenovirus Serotype 5 [2, 33, 196-198] 
Protein Number  Protein Name  Size (kDa)  Number Per Virion  Known Functions 
II  Hexon monomer  110  720  Structural; liver tropism 
III  Penton base  63  60  Structural; binds cellular integrins 
IIIa  Cement protein  63  60  Associated with penton base 
IV  Fiber  62  36  Primary attachment protein 
V  Core protein  42  160  Associates with DNA and penton to connect the nucleocore and capsid 
VI  Cement protein  23  ~360  Endosomal lysis and escape; imports hexon into the nucleus for viral assembly 
VII Core  protein  19  840  Histone-like 
VIII Cement  protein  15  120 
Associated with underside of hexon capsid;  
Stabilization/assembly of particle? 
IX  Cement protein  14  240  Stabilization/assembly of capsid 
TP  Terminal Protein  55  2  Protein primer for genome replication 
X  Mu  4  100  Nucleoprotein; Genome replication? 
IV2a Nucleoprotein     Genome  packaging 
  Protease  23  ~10-12  Viral protein processing and maturation 
 
integrins triggers Ad5 internalization via receptor-mediated 
endocytosis on clathrin-coated pits. The virions are subse-
quently able to escape from endosomes and traffic to the 
nucleus within 30 to 60 minutes of cell binding on permis-
sive cells (reviewed in [12]). If the fiber receptor is absent or 
if CAR binding is ablated on knob, the virus can bind more 
slowly by lower affinity interaction of penton base with in-
tegrins. In this circumstance in vitro, short (1 hour) exposure 
of CAR-negative cells with Ad5 results in poor transduction 
whereas longer (24 hour exposure) can mediate very high 
transduction (e.g. Ad5 on K562 cells [36] and data not 
shown). If cells lack CAR and integrins, they are relatively 
(but not absolutely) resistant to Ad5 infection.  
 This  in vitro infection paradigm is based on Ad5 and Ad2 
infection in cell culture. These rules apply to some extent to 
other Ad species and serotypes with some minimal to drastic 
variations. For example, other species C Ads behave 
similarly to Ad5 in vitro, although the fiber of Ad6 is three 
repeats shorter – perhaps making its yoga process somewhat 
less efficient [37]. In contrast, most other species of human 
Ads have markedly shorter fibers than Ad5 (with only 6 or 8 
shaft repeats) creating a disconnect between being flexible 
enough to bind a receptor and being able to use a receptor for 
cell infection. These shorter shafted fibers may target recep-
tors that are directly endocytosed such that integrin interac-
tions are less important. 
  For example, the fiber for species D Ad37 can bind to 
CAR, CD46, and sialic acid. However, it appears only able 
to use sialic acid as a receptor for infection [18, 38, 39]. This 
effect may be due to the very short length of species D fibers 
with only 8 -spiral repeats. These fibers may lack sufficient 
flexibility or length to allow functional combination receptor 
utilization such as Ad5 can perform between CAR and in-
tegrins. Similar effects are observed with short species B 
viruses Ad35 that have fibers with only 5.5 repeats. These 
viruses are able to use CD46 or other receptors efficiently 
with these shorter shafts [40]. However, if CAR-utilizing 
viruses are given short shafts, this abrogates effective com-
bination of CAR and integrin and infectivity is markedly 
reduced.  
  Short-shafted fibers may also enable Ads to use integrins 
more efficiently as primary receptors. For example, compari-
son of species D Ad8, 9, 19, 19a, and 37 demonstrated that 
Ad8, 19a, and 37 use sialic acid as a functional receptor, 
whereas Ad9 and19 appeared to use v integrins as their 
primary receptor in vitro [38]. In our recent screen of species 
D Ads for infection of B cell cancers, we observed that most 
were largely independent of sialic acid for infection, but in-
stead used a combination of CD46 and v integrins for infec-
tion and killing [41]. Therefore, longer fibers appear to cre-
ate more steric hindrance with penton-integrin interactions 
and may require more flexibility. In contrast, shorter shafted 
fibers may obstruct penton-integrin interactions to a lesser 
extent and better use this infection pathway on cells.  
ADENOVIRUS PHARMACOLOGY IN VIVO 
Interactions with Blood Factors Impart Tropism 
  Given that both fiber and penton have receptor-binding 
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"detargeting"[42]. While mutations to ablate CAR and in-
tegrin binding worked as expected in vitro, they had surpris-
ingly weak effects on in vivo tropism [43, 44]. Subsequent 
seminal work suggested that the difficulty in altering the 
tropism of Ad5 was actually due to unexpected interactions 
of the virus with host proteins in vivo [45]. Initial studies 
indicated that Ad fiber can bind blood factors like FIX and 
C4BP with moderate affinity [45]. However, later studies 
independently concluded that hexon, not fiber, was the main 
protein interacting with blood factors [46-48]. These studies 
showed that factor X (FX) binds Ad5 hexon with nanomolar 
affinity and that FX then targeted the virus to receptors on 
hepatocytes. Comparison of FX binding to select Ads from 
different Ad species demonstrated that approximately half of 
the tested viruses bind FX [48].  
  Blood factors I to XIII and Protein C (PC) are produced 
in the liver as zymogens and are activated by cleavage for 
use in normal blood clotting. Vitamin K dependent blood 
factors VII, IX, X and protein C enhance transduction of 
Ad5 in vitro [45, 46]. These factors share the common do-
main structure GLA-EGF1-EGF2-SP, where SP is the cata-
lytic serine protease domain, EGF1 and EGF2 are epidermal 
growth factor-like domains, and the GLA domain is a hexon-
binding glutamate rich domain [46, 47, 49, 50]. On the other 
hand, non-homologous factors (FXI and FXII) do not en-
hance transduction [46]. Upon production in the liver, zy-
mogens containing the GLA domain are carboxylated in a 
vitamin K dependent manner on the -carbon of each of their 
9-12 glutamic acid residues [24]. In vivo, physiologic levels 
(8-10 μg/ml) of these -carboxylated blood factors results in 
hepatocyte transduction even for CAR-ablated viruses. Con-
versely, inhibition of this post-translational vitamin K de-
pendent  -carboxylation with warfarin markedly decreases 
hepatocyte transduction by Ad5 [46]. FX binding to hexon is 
highly calcium dependent and can be inhibited by chelation 
with EDTA. This is unsurprising, as the GLA domain binds 
seven calcium ions, while the EGF1 and SP domains each 
bind one. As a result, the absence of the GLA domain ren-
ders Ad5 unable to bind FX (as measured by surface Plas-
mon resonance) and thus unable to transduce hepatocytes 
[47, 48]. 
  Binding of the GLA domain of FX to Ad virions appears 
to orient the SP domain of FX to bind heparan sulfate pro-
teoglycans (HSPGs) on cells. After i.v. injection, this ap-
pears to yield selective infection of hepatocytes. However, 
HSPGs are ubiquitously found on the cell surface and on 
extracellular matrix proteins, so the mechanism of specific 
uptake into hepatocytes is unclear. Recently, Bradshaw et al. 
showed evidence that a high level of N- or O-sulfation (“sul-
fation signature”) on heparan sulfate in the liver is necessary 
for FX mediated Ad infection, thus accounting for liver 
specificity [51].  In addition, the fenestrated vasculature of 
the liver provides easy access to hepatocytes as opposed to 
other tissues where these “windows” are not present. 
  Ads display seven hypervariable region (HVR) domains 
on their hexon proteins that vary in sequence between sero-
types [52] and are primary targets for neutralizing antibodies 
[53, 54]. Variations in these HVRs appear to correlate with 
FX binding affinity and with the ability of Ad serotypes to 
transduce hepatocytes [47]. Cryo-electron microscopy of 
Ad5 identified FX density near the central depression of the 
hexon trimers near the HVRs [47, 48]. Mutational analyses 
of Ad5 hexon suggested interactions of FX with HVR5 and 7 
[55]. More precisely, a point mutation of glutamic acid 451 
that is conserved in FX binders partially abolished binding of 
FX to the virus [55].  
  These data suggest roles for HVR5 and 7 in FX binding. 
However, even within Ad5's own species C viruses, there is 
marked variation in liver transduction; Ad5 and Ad6 are 
most robust and Ad1 and Ad2 are markedly less effective 
[37]. When the HVRs of these viruses are compared, only 
the HVR1 and 4 genotypes cluster with the higher liver 
transduction phenotype. This is interesting given that the 
HVR1s of Ad5 and Ad6 have considerable negative charge 
(net negative charge of 13 and 8). At the same time, the GLA 
domain of FX displays 7 or more Ca
2+ and ions, it is interest-
ing to speculate that binding or perhaps initial docking of FX 
with hexon may be facilitated by FX interaction with HVR1. 
Given that HVR1 is unstructured in x-ray crystals, interac-
tions with this loop cannot be modeled easily. Therefore, 
targeted mutation of HVR1 has not yet been tested.  
  These observations induced a paradigm shift in Ad biol-
ogy by demonstrating that in vivo tropism of some Ads is 
mediated not just by ligands on the virus, but also by host 
factors. This showed that Ad5 is an excellent choice of vec-
tor for liver-directed gene therapy as it has natural tropism to 
the liver upon systemic injection and can transduce hepato-
cytes with high efficiency. Conversely, Ad5 may be a poor 
choice for therapy beyond the liver, since the bulk of the 
virus is depleted in the liver. Whatever the intended target 
tissue, a deeper understanding of Ad pharmacology reveals 
that host sequestration mechanisms can result in only a frac-
tion of the injected dose reaching its intended location. Here 
we outline the obstacles that Ad encounters in vivo in order 
to further inform the optimal design of Ad vectors.  
Interactions with Blood Cells and Proteins 
  Upon intravenous delivery, evidence suggests that Ad5 
interacts with a number of soluble proteins including natural 
antibodies, complement [56] and blood clotting factors [45-
48]. These adsorptions likely occur immediately after virus 
injection into the blood stream. Natural antibodies are circu-
lating antibodies not induced by individual antigens, but en-
coded by the germline against common structures. Conse-
quently, they are broadly specific, tend to have low affinity, 
and provide naive hosts immediate defense against invading 
pathogens like bacteria and viruses [57]. Natural antibodies 
somewhat compensate for their low affinity with high avidity 
and are predominantly IgM. Thus, natural antibodies also 
serve as a potent complement activator, although Ad5 can 
also bind directly to complement proteins from the classical 
and mannan-binding lectin pathways [56, 58].  
  Studies have observed binding of complement protein C3 
to the Ad capsid in the presence of factor B and factor D, 
proteins involved in the antibody-independent alternative 
pathway of complement activation [59, 60]. Interestingly, 
complement protein C1q was shown to increase transduction 
in CAR negative cells [61]. On the other hand, complement 
binding to adenovirus is immunostimulatory, and can been 
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peptide into fiber or pIX of the viral capsid [62]. Notably, the 
mechanisms of complement activation in vivo have been 
shown to be different than the mechanisms derived in vitro. 
In vitro, antibodies are required for C3a binding and subse-
quent activation of the classical complement pathway. In 
vivo, antibodies are not required for C3a binding, and activa-
tion can occur through both classical and non-classical path-
ways [58]. 
  Complement binding can lead to clearance of the virus 
via macrophage uptake, but recently it was also shown to be 
involved with sequestration of the virus on erythrocytes. 
Carlisle et al. found that Ad5 appeared to interact with com-
plement factors which then act as bridge for binding to hu-
man complement receptor 1 (hCR1) on erythrocytes [63]. 
Murine erythrocytes displaying hCR1 significantly decreased 
the amount of Ad5 able to transduce the liver in vivo (16 
fold). Furthermore, CAR is also displayed on human, but not 
murine, erythrocytes despite its role as a cell adhesion mole-
cule. As erythrocytes are not productively transduced, they 
can therefore act as a substantial sink for any systemically-
administered Ad [64].  
  In addition to human erythrocytes, the majority of human 
thrombocytes (72%) are also positive for CAR [65]. Al-
though CAR has not been tested as the specific mediator for 
the interaction, platelet pull downs and transmission electron 
microscopy reveal that Ad5 binds directly to thrombocytes 
and activates them [66]. The von Willebrand factor, one of 
the proteins released during platelet degranulation, is impli-
cated in causing platelet-leukocyte aggregates as well as the 
widely observed phenotype of Ad5 induced thrombocy-
topenia [65]. 
Systemic Distribution of Adenoviruses 
  When delivered i.v. directly into the bloodstream, Ads 
will be delivered to the heart via the inferior or posterior 
vena cava, be pumped through the lungs, and then be sent to 
the periphery via the aorta and arteries (Fig. 3A). Free or 
bound virus can circulate through the body to encounter any 
cell or tissue in contact with the blood. An intravenous (i.v.) 
dose of Ad will likely first encounter the heart and lungs 
before being distributed to the liver, spleen, and kidneys 
(Fig. 3A). Furthermore, general endothelial cells lining the 
vasculature throughout the body may theoretically be a huge 
sink for any Ad serotype. While there is evidence that Ad5 
and other serotypes infect endothelial cells, these interactions 
do not appear to be particularly productive, perhaps due to 
low levels of cognate receptors [67, 68]. To what degree 
bulk endothelial cells differ from liver sinusoidal endothelial 
cells (LSECs) in Ad interactions is unclear. Obvious differ-
ences relate to the ability LSECs to form fenestrations and to 
pinocytose material (see below).  
  The body eliminates most compounds, including Ads, 
through the natural filtering functions of the liver and kid-
neys. Water-soluble items can be removed by the kidney and 
hydrophobic compounds are generally metabolized in the 
liver for subsequent excretion in the gut or in the kidney. 
While Ads can and do accumulate in a variety of organs, the 
liver appears to be the principal sink for prototype Ad5 virus. 
This filter function is demonstrated in elegant pharmacologic 
studies in mice. At doses up to 4x10
12 vp/kg of Ad5, ap-
proximately 98% of injected virus is found in the liver 30 
minutes after injection [69]. At this same dose, only about 
1% of injected Ad5 can be found in either the lungs or the 
kidney at this dose. If the dose is increased 4-fold, Ad5 in the 
liver falls to 85% of injected dose and virus in the spleen and 
lung rises to 6 and 5% of injected dose, respectively.  
  It should be noted that when normalized to organ weight 
(i.e. specific activity instead of total activity) the spleen can 
appear to express Ad5 nearly as well as the liver [70]. This 
representation is helpful for understanding adenoviral biol-
ogy, but may minimize the true effect of the virus in vivo 
since the liver is substantially larger. Such analyses become 
appropriate in terms of generating immune responses to Ad 
or its transgene products, since total expression of the immu-
nogenic epitopes is more relevant than specific activity  
VECTOR SEQUESTRATION IN THE LIVER 
  Liver sequestration is remarkably fast as we demon-
strated recently using near-infrared (NIR) fluorescent imag-
ing in mice [71]. Ad5 was labeled with the NIR fluorophore 
IR800 and injected i.v. into the jugular vein. By fast image 
capture (250 millisecond exposures every 0.5 millisecond), 
virus could be seen entering the heart within 500 millisec-
onds of injection. Within 7 seconds, the viral swarm was 
observed in arterial outflow throughout the mouse. Virus 
then returned from the periphery and began accumulating in 
the liver. Within 3 minutes of injection, the bulk of virus 
distribution was essentially complete with the vast majority 
being localized to the liver and less so to the spleen and kid-
neys [71].  
  In humans, approximately 1.5 liters of blood is delivered 
into liver sinusoids from the portal vein and hepatic artery 
every minute for filtration (Fig. 3B, C, and D). Particulates 
like Ad that enter liver lobules and their sinusoids encounter 
Kupffer cell macrophages and LSECs that serve as gate-
keepers for the liver (Fig. 3C and D). There is some evidence 
that Ad5 that is ensnared on platelets, is trafficked to the 
liver, and also likely trafficked to the spleen. Indeed, throm-
bocytes may deliver viral particles to resident liver macro-
phages, also known as Kupffer cells, within minutes of intra-
venous injection. Depletion of platelets prior to adenovirus 
injection in one model was able to decrease the amount of 
viral DNA in the liver [66]. In contrast, blood factor binding 
or platelet binding to Ad5 was not found to contribute to 
Kupffer cell uptake in other studies [56]. Therefore, it is 
somewhat unclear whether platelets play a role in delivery of 
Ad5 and other serotypes to liver Kupffer cells. 
  Viruses that escape both Kupffer cells and LSECs can 
enter the space of Disse through fenestrations in the LSECs 
(Fig. 3C and D). Once in the parenchyma, virions can inter-
act with hepatocytes via evolved or captured cell binding 
ligands to mediate transduction or liver damage depending 
on serotype. Viruses that fail to infect hepatocytes after entry 
into the space of Disse are presumably captured in the lymph 
from the lobules and delivered to draining lymph nodes (Fig. 
3D). If viruses are transcytosed (perhaps by engaging caveo-
lin rather than clathrin entry pathways) they could theoreti-
cally be ejected on the other side of the hepatocytes into the 
bile (Fig. 3D). The effects or level of virus distribution, 
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liver remain largely unexplored. Given their likely delivery 
to mucosal and immune cell education sites, these routes of 
virus distribution may have profound effects on immune 
responses against Ads and their transgene products.  
Kupffer Cells 
  Kupffer cells (KCs) are the resident macrophage of the 
liver and are essential in removing foreign particles and 
pathogens from the blood stream (Fig. 3C and D). Although 
they comprise only ~7% of liver cells, they estimated to ac-
count for 80-90% of all of the macrophages in the body [72, 
73]. It has been estimated that liver Kupffer cells can seques-
ter up to 98% of intravenously injected Ad5 vector in mice 
[74]. These interactions are thought to be predominantly 
phagocytic and non-productive for infection, since this up-
take triggers massive destruction of virions and the Kupffer 
cells [74, 75]. However, a small proportion of virions that 
interact with Kupffer cells may enter by integrin binding to 
mediate low level transduction of these cells [76]. For exam-
ple, at very high doses of Ad5 (1 x 10
11 PFU/kg), 70% of 
hepatocytes and 15% of Kupffer cells expressed transgene 
three days later [76].  
  Scavenger receptor A (SR-A) is a broadly specific scav-
enger receptor expressed on the surface of Kupffer cells that 
is thought to recognize net negative or positive charge [56]. 
Injection of negatively charged polyinosinic acid, or poly(I), 
into mice prior to injection of Ad5 transiently increased viral 
circulation in the blood 10-fold; transgene expression in-
creased in a variety of tissues by 5- to 15-fold [77]. The hy-
pervariable region 1 (HVR1) on Ad5 hexon in particular has 
large amounts of charged residues and has therefore been 
implicated in Kupffer cell recognition [74]. On the other 
hand, Kupffer cells in wild-type and SR-A knock out mice 
appeared to take up similar amounts of Ad5, suggesting that 
Kupffer cells have alternate or redundant mechanisms for 
viral recognition [68].  
Liver Sinusoidal Endothelial Cells (LSECs) 
  Liver sinusoidal endothelial cells (LSECs) are also a ma-
jor component of the reticuloendothelial system (RES) al-
though their role in phagocytosis of particles like Ad is un-
derappreciated [78]. LSECs line the sinusoids of the liver 
and represent ~25% of liver cells ([72] and Fig. 3C and D). 
Like Kupffer cells, LSECs express scavenger receptors 
SREC 1 and SREC-II that may be candidates for uptake of 
Ad particles [79]. LSECs work in concert with Kupffer cells 
to clear material from the bloodstream. Unlike Kupffer cells 
that can engulf particles up to 2 m in diameter, LSECs re-
move particles under 230 nm in diameter by pinocytosis [78, 
80]. Therefore, both cell types of have an overlapping ability 
to remove Ads from the circulation, although an increase in 
the effective diameter of Ad virions upon binding to other 
circulatory factors may favor uptake by Kupffer cells. Inter-
estingly, when Kupffer cell uptake was impaired, LSECs 
were able to take up particles >1 m in diameter [80]. 
Sequestration of Ad by vascular endothelial cells is unclear, 
although in situ experiments show that like LSECs they are 
poorly transduced even at high doses [81].  
 
 
 
 
 
 
 
 
 
 
Fig. (3). Adenovirus delivery upon systemic injection. (a) Distribution of virion delivery including largest pharmacologic “sinks”. 1 = 
Liver, 2 = Spleen, 3 = Kidney, 4 = Lung, 5 = Bloodstream.  Schematic of viral migration from the blood stream into the parenchyma of liver: 
(b) within the lobule structures of the liver and (c,d) within one lobule.  (c) represents flow of virus from the triad to the central vein looking 
down into the sinusoid.  (d) represents permeation of virus from inside the sinusoid out into the parenchyma via fenestrations.  (d) also shows 
other pharmacologic paths virions may take including outflow in the the lymph and bile. 
bile
fenestrations
(~50-240 nm)
space of Disse
Ad
(~92 nm)
sinusoid
(5 µm diameter)
Kupffer
cell
hepatic artery
portal vein
lymph
central vein
hepatocytes
LSECs
1 2
3
4
5
AB C
CV
lobule
portal
triad
D248    Current Gene Therapy, 2011, Vol. 11, No. 4  Khare et al. 
  Like Kupffer cells, LSECs are inefficiently transduced by 
Ad5, showing no expression at <100 infectious units 
(IU)/cell, and meager expression at >1000 IU/cell in vitro. In 
contrast, 100% of hepatocytes are infected by Ad5 at 5 
IU/cell. Similar results have been observed in vivo. For ex-
ample in mice, no transduction of Kupffer cells or LSECs 
was observed after injection of Ad5 [82].  
The Effects of Host Species and Strains on Adenovirus 
Pharmacology  
  The complexity and crucial differences in uptake of Ad5 
by the liver is reflected in direct comparisons of transgene 
expression in various inbred mouse strains. At a moderate 
dose of 1 x 10
10 vp Tao et al. demonstrated a ~400-fold range 
of variation in Ad5 liver transduction in NCR nude, 
C57Bl/6, BALB/c, C3H, and Rag-1 mice. Higher doses of 8 
x 10
10 vp, which test expression effects after exceeding the 
Kupffer cell “threshold” show a different profile of expres-
sion in these mice, with a 30-fold range in variability [83]. 
Snoeys et al. determined that BALB/c mice take up ~6-fold 
more Ad DNA in their non-parenchymal cells than C57BL/6 
mice. When analyzed by cell type, they showed that BALB/c 
mice sequestered ~20 times more Ad DNA in their Kupffer 
cells than C57BL/6 mice after i.v. injection [84]. Conversely, 
C57BL/6 mice took up more virus in their LSECs rather than 
in their Kupffer cells. Interestingly, they found that the over-
all number of Kupffer cells between the two mouse strains is 
not significantly different, suggesting that fundamental dif-
ferences in the location, types, and/or density of receptors 
responsible for Ad uptake may be significantly disparate 
between animal strains. 
  Electron microscopy shows that LSECs form sieve plates 
with fenestrations [85, 86] that allow Ads to reach the paren-
chyma of the liver and hepatocytes [87, 88] (Fig. 3). How-
ever, fenestration sizes can be highly variable between spe-
cies: >150 nm for Sprague Dawley rats, 141 nm for C57Bl/6 
mice, 103-105 nm for two strains of rabbits and 107 nm for 
healthy human livers [72, 89].  
  These data have been used to propose that the effect of 
Ad in humans may not be predicted by murine models. 
While this may be the case, it should be noted that these fen-
estration measurements are mean sizes, not an absolute cut-
off. For example, the mean fenestration size in healthy hu-
man livers were reported as 107 nm although diameters may 
reach up to 240 nm in diameter [72, 89]. Indeed, in human 
liver, more than half of the measured fenestrations exceeded 
the diameter of Ad. These theoretical calculations are sup-
ported by human data. For instance, increases in liver en-
zymes are routinely observed when human patients have 
been injected with replication-competent, replication-
selective, or replication-defective Ad5 by intravascular injec-
tion or even after intratumoral injection [90-92], suggesting 
that virus must be reaching hepatocytes in order to stimulate 
such release.  
  Our original tests of Ad pharmacology were performed in 
outbred mice to avoid the effects of inbreeding in favored 
mouse strains [67, 70, 88]. As we have moved to evaluating 
immune responses to Ad and its transgenes and utilizing 
genetically modified mice, we have transitioned to working 
in inbred strains or on different inbred genetic backgrounds 
[23, 93-96]. We have found that the genetic background of 
the mice can have profound effects on the pharmacology of 
Ad as evidenced by recent work in our laboratory. Compari-
sons of BALB/c, C57BL/6, FVB, 129, nude, and hairless 
HRS mice demonstrate considerable differences in raw gene 
expression in the liver after intravenous injection and after 
manipulating the levels of Kupffer cells prior to injection 
([94, 95] and unpublished data). The use of different strains 
of mice may explain some diametrically-opposed results in 
the literature particularly regarding the effects of Kupffer 
cell depletion and why certain strains of mice will respond to 
gene therapy and others will not. Until the key biologies are 
identified that control these pharmacologic effects and how 
they apply in humans, the best approach is to test Ad phar-
macology in several strains and in other species. 
Beyond the Liver 
  The discussion above has focused on what we currently 
consider the “biggest” initial steps and barriers that adenovi-
ruses encounter after an intravenous injection. Beyond the 
blood, vascular endothelial cells, and the liver Big Three (i.e. 
Kupffer cells, LSECs, hepatocytes), there are of course other 
cells within the liver that likely encounter and interact with 
adenoviruses (i.e. liver dendritic cells, stellate cells, lympho-
cytes, etc.). Beyond the liver, we know that a smaller, but 
significant fraction of Ad lands in the spleen, kidneys, and 
lungs after intravenous injection (Fig. 3A). Indeed, different 
serotypes of Ad are likely to permeate to many sites that we 
currently do not have the sensitivity to track (other organs, 
tissues, lymphatics, etc.). These locations also impact the 
pharmacology and, importantly, immune responses against 
Ads and their transgenes.  
ADENOVIRAL VECTOR DETARGETING 
  The vast majority of early work to modify Ad tropism 
was directed at retargeting the virus to new receptors. Subse-
quent work aimed to detarget Ad from its cognate in vitro 
receptors. When these efforts have been applied in vivo, they 
have generally failed for lack of decent targeting ligands and 
because of limited understanding of Ad pharmacology in an 
intact body. The revolutionary observations concerning the 
depletion of Kupffer cells by Ad and the unexpected effect 
of clotting factors on Ad pharmacology have opened up a 
new area to apply effective detargeting strategies. We hy-
pothesize that once we can detarget the wrong cells effec-
tively in vivo, then retargeting with new ligands may begin to 
succeed. However, we may need to know all of the cells and 
proteins that are mistargeted before detargeting will be opti-
mal.  
Evading Blood Proteins and Cells 
  After intravenous injection, Ads bind proteins and cells 
in the blood. As some of these interactions are ligand-
receptor driven (i.e. hCAR and hCR1 receptors on erythro-
cytes, etc.) the use of alternate serotypes may attenuate some 
effects. Other approaches are to genetically-delete these 
evolved viral ligands to specifically detarget CAR, CD46, 
integrin, and other interactions [68].  
  Another approach to evade interactions is to coat Ads 
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glycol (PEG) and poly-N-(2-hydroxypropyl) methacrylamide 
(HPMA) ([64, 67, 69, 70, 74, 88, 93, 97-111] and see be-
low). 
  Polyethylene glycol (PEG) is a stable, uncharged, hydro-
philic, and synthetic polymer widely used in food and drug 
industries. Made up of repeating units of ethylene oxides 
(CH2-CH2-O-) it can be synthesized in multiple shapes (e.g. 
branched and linear) and varying lengths (resulting in mole-
cules up to 40 kDa in size). PEG can be manufactured with 
functional groups on their one or both of their termini, result-
ing in its use as a versatile chemical modifier for adenovirus. 
Heterobifunctional PEGs have functional groups on either 
end of the molecule. This enables its use as a linker mole-
cule, or can be useful in detection of PEGylated virions. For 
instance, heterobifunctional PEG such as Alexa488-PEG-
maleimide can be covalently linked to cysteines on the cap-
sid of Ad5, thus tagging it with a fluorescent marker [112]. 
  HPMA is a hydrophilic polymer composed of an unreac-
tive carbon chain backbone with diglycyl side chains. Ap-
proximately 10 amino-reactive 4-nitrophenoxy groups are 
incorporated into these side chains per 100 monomers of the 
backbone. Thus, HPMA is a multivalent polymer and can 
interact with an Ad capsid at multiple locations like a zipper.  
  Both of these polymer approaches prevent interactions of 
Ad with a variety of blood proteins and cells. For example, 
PEGylation of Ad5 blocks CAR binding, thereby eliminating 
interactions with any CAR-expressing cell [70]. For exam-
ple, PEGylation and/or HPMA modification blocks binding 
and activation of platelets, red blood cells, and endothelial 
cells by Ad5 [64, 67, 113]. These effects in the blood or tis-
sues have substantial abilities to reduce innate immune re-
sponses and liver damage after i.v. injection of Ad. However, 
random polymer modification can inhibit virus function [70]. 
Therefore, approaches to target PEGylation to specific sites 
on Ad by using maleimide-PEG to react with inserted cys-
teines may reduce interactions with blood cells while pre-
serving virus activity [95, 105, 106, 114]. 
Evading the Liver: Kupffer Cells 
  In mice, 98% of a low dose of Ad5 is found in the liver 
30 minutes after i.v. injection [69] and little hepatocyte trans-
duction is observed due to sequestration of Ad5 by Kupffer 
cells and LSECs. This sequestration can be overwhelmed 
with higher doses [115], but this also increases toxic side 
effects. An alternate approach is to "predose" the system by 
injecting gadolinium chloride, chlodronate liposomes, or 
high doses of Ad5 to saturate and kill Kupffer cells before 
injecting the therapeutic or reporter virus [74, 116-120]. For 
example, predosing mice with Ad5 before injection of Ad5-
luciferase increases hepatocyte transduction 44-fold [120]). 
Therefore, by eliminating Kupffer cells (and likely other 
cells like LSECs) with a first dose of Ad5, more functional 
virus is available to reach distant sites. In this case, when 
using a hepatocyte-tropic Ad5 the next downstream func-
tional targets are hepatocytes that are effectively transduced 
by the virus. When performing oncolytic therapy against 
distant tumors, predosing increases the ability to kill tumors 
systemically [120]. Manickan et al. showed that in 
sequestering Ad5 virions, Kupffer cells themselves are de-
stroyed [75]. Therefore, while liberated virions can escape 
for more distant delivery, this process is highly inflammatory 
and Kupffer cell evasion, rather than destruction, may be a 
preferable method [75, 121].  
  To what degree other Ad serotypes are trapped in the 
liver is still under investigation. Despite their close homol-
ogy, preliminary comparison of species B Ad11 and 35, spe-
cies C Ad5 and 6, and species D Ad26 and 48 for predosing 
demonstrated that Ad5 was by far the most effective at ena-
bling a subsequent dose of Ad5-luciferase to transduce hepa-
tocytes ([122] and data not shown). While this suggests that 
other Ad species may not be adsorbed by Kupffer cells, these 
other serotypes may be encountering sinks of their own, 
since they are not entirely neutral and some actually cause 
lower subsequent expression in hepatocytes. Closer examina-
tion of Ad6 suggests that it may evade Kupffer cells much 
better than Ad5 [14, 94]. Indeed, Ad5 and Ad6 are substan-
tially better at liver-directed gene therapy than their family 
members Ad1 and 2 [14].  
  PEGylation of Ad also appears to be an effective means 
to detarget Kupffer cells. Random conjugation of suc-
cinimide-activated NHS-5 kDa PEG to Ad5 mediated 
marked reductions in Kupffer cell uptake in mice [70]. Inter-
estingly, while this reduced many side effects (IL-6, throm-
bocytopenia, etc.), PEGylation did not appear to reduce up-
take of virus into splenic cells (unpublished observations). 
Follow up testing of this approach with replication compe-
tent oncolytic Ad5 with different-sized NHS-PEGs (5, 20, 
and 35 kDa NHS-PEG) showed that 5 kDa PEG increased 
hepatocyte transduction, presumably by detargeting Kupffer 
cells [88, 107]. In contrast, larger PEG appeared to detarget 
both Kupffer cells and hepatocytes as evidenced by reduced 
liver expression. One possible cause for this reduction may 
lie in the failure of virions to access hepatocytes via fenes-
trae, due to the increase in virion diameter upon PEGylation. 
This dramatic increase in viral expression is not dependent 
on complete coating of the viral capsids, but could be repli-
cated with specific conjugation of 5 kDa PEG into only the 
HVR5 loop of Ad5 hexon [114]. Subsequent systematic tar-
geted PEGylation of HVR1, 2, 3, 4, 5, 6, and 7 in Ad5 dem-
onstrated that shielding HVR1, 2 and 5 produced up to 20 
fold increases in hepatocyte transduction whereas modifica-
tion of the other HVRs had less effect [95]. Given that 
Kupffer cells are thought to phagocytose Ad5 via scavenger 
receptors, shielding the multiple negative charges 
particularly in HVR1 with this hydrophilic polymer likely 
mediates much of the protective effects on the virus. 
Evading the Liver: Hepatocytes 
  Based on the Ad5 prototype in mice, it appears that much 
of intravenously injected virus is sequestered by Kupffer 
cells and possibly by LSECs. Some fraction of any injected 
dose can escape these cells to go on to transduce hepatocytes 
or go further to infect extra-hepatic tissues. Kupffer cell de-
pletion or evasion allows Ad5 virus to enter the next viral 
sink, which for this hepatotropic virus are hepatocytes, 
which yields productive transgene expression. If another Ad 
serotype is used that is less hepatotropic (e.g. due to lack of 
FX binding), then hepatocytes may not be the next viral sink, 
but it may be another tissue downstream. It appears that ap-
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[47], so these may be good platforms for hepatocyte evasion 
provided they do not infect the cells by other mechanisms. 
  Gene delivery by Ad in the liver occurs because of pro-
ductive expression in hepatocytes [75, 83, 116-119, 123]. 
One method of hepatocyte detargeting uses pharmacologic 
ablation. In this case, warfarin can be used to inactivate vi-
tamin K-dependent blood clotting factors and reduce Ad5 
delivery to hepatocytes [120, 124]. While this is feasible in 
mice, achieving such low levels of FX in humans would 
likely be prohibitive given its effects on clotting. Modeling 
based on cryo-EM suggested that FX may interact with hy-
pervariable (HVR) loops 3, 5 and 7 on Ad5 [125]. Similarly, 
insertion of peptides such as the biotin acceptor peptide 
(BAP) into HVR5 of replication competent Ad5 has demon-
strated reduced expression of the luciferase transgene and 
increased expression in orthotopic tumors, thus extending 
survival [126]. 
  While polymer modification of Ad may be expected to 
block Ad5-FX interaction, PEGylation appears to block Ad5 
liver transduction directly. Indeed, random NHS PEGylation 
and targeted maleimide PEGylation both appear to preserve 
the ability of FX to bind to Ad5 virions [88, 95]. Given that 
RGD-integrin interactions appear functional on hepatocytes 
[68] and that integrin interactions are preserved after PEGy-
lation [70], this interaction may be involved in maintaining 
hepatocyte transduction in the case of small PEGs. In con-
trast, large PEGs (20 kDa, etc.) may make the virus too big 
to cross fenestrae and/or use integrin associations, and there-
fore they may be used as a means to detarget hepatocytes. 
Evading the Liver: LSECs 
  Kupffer cells are thought to be the biggest sink for Ad5 
in the liver, depletion of them by predosing surprisingly does 
not reduce the number of vector genomes in the liver [120, 
127]. Combined predosing and warfarin improve oncolytic 
killing of distant tumors after i.v. injection, but these two 
detargeting strategies nevertheless do not significantly de-
crease viral genomes in the liver or increase viral genomes in 
the tumor at short time points [120]. In contrast, when Koski 
et al. treated mice with warfarin to deplete vitamin K de-
pendent blood factor interactions, anti-platelet antibodies, 
and Kupffer cell scavenger receptor blockers into mice prior 
to Ad injection, the combination of these treatments yielded 
an 81% increase in tumor to liver ratio of virus [128]. 
  These data suggest that virus may be sequestered by 
other cells of the liver. To address this, Shayakhmetov's 
group tested Kupffer and hepatocyte detargeting strategies 
combined with integrin detargeting by ablation of the RGD 
motif in Ad5 [68]. They showed that no single intervention 
by itself fully detargeted the virus from the liver. Rather, 
only when all three interventions were applied were signifi-
cant reductions in viral sequestration observed. In particular, 
ablation of integrin binding appeared to detarget LSECs and 
hepatocytes, emphasizing the roles of both Kupffer cells and 
LSECs in viral trapping. Therefore, detargeting all three cell 
types (and maybe more) appears important to liberate virus 
for systemic delivery.  
  Since PEG and HPMA polymers tend to reduce protein-
protein interactions, it is not surprising that coating Ads with 
these hydrophilic polymers also has effects on interactions 
with endothelial cells. For example, coating Ad5 with 5 kDa 
PEG reduces infection and activation of human endothelial 
cells in vitro [67]. In vivo, PEGylation of Ad5 also reduces 
interactions with liver LSECs as evidenced by reduced 
upregulation of E-selectin messenger RNA [67].  
Evading Other Cells and Tissues 
  Progress is being made to avoid Kupffer cells, LSECs, 
and hepatocytes in the liver. As this predominant adenoviral 
trap is avoided, it is likely that new ones will surface. Cur-
rently, the spleen appears to be the next biggest pharma-
cologic sink, at least in mice [70]. The spleen appears to trap 
viral genomes approximately 3 times more than the liver in 
terms of viral to host genomes. Again, this is specific activity 
per unit tissue, so total amount of expression and viral ge-
nomes is profoundly higher in the liver.  
  Splenic uptake likely occurs due to entrapment on blood 
cells and direct capture by macrophages. For instance, after 
i.v injection in mice the weight of the spleen increases 200% 
over the following 7 days [67]. When Ad5 is injected i.v. 
into splenectomized mice, the level of virus in the blood in-
creases approximately 300% [67]. In the absence of a spleen, 
innate immune responses are also reduced 25% suggesting 
roughly that one quarter of the response is generated or 
modulated in this organ.  
  Beyond the spleen, the lung is a likely sink by direct in-
fection and also by the curious effect Ad5 (and perhaps other 
serotypes) has on Kupffer cells. Ad5 kills Kupffer cells 
within minutes of uptake [75] and ~4 hours later, the dead 
Kupffer cell fragments are released into the circulation. Like 
most large aggregates, these Kupffer cells are filtered from 
the circulation by the lungs and Ad-infested Kupffer cell 
remnants can be found in pulmonary capillaries. To what 
degree Ad remains active for gene delivery remains to be 
determined, particularly when replication-competent instead 
of replication defective virus is used. Indeed, Smith et al. 
have shown that cirrhotic rats actually suffer from substan-
tially higher lung toxicity after Ad dosing than normal ani-
mals [129]. Therefore, evading Kupffer cells altogether may 
reduce transfer of virus to sites like the lung. 
PROTECTING ADENOVIRUS FROM THE IMMUNE 
SYSTEM 
  Host sequestration, viral traps, and pre-existing immunity 
necessitate the use of vastly larger doses of intravenously 
delivered vector for liver-directed or systemic therapy. How-
ever, as Ad capsids are known to be potent immunogens, 
delivering high doses of any Ad serotype will likely provoke 
hemagglutination, the formation of immune-complexes, acti-
vation of complement, recruitment of immune cells, the 
rapid and wide release of proinflammatory cytokines, and 
thus vigorous tissue damage (discussed in our original re-
view). Given that adenoviruses are infectious agents, humans 
have widespread pre-existing immunity to different Ad sero-
types. Similarly, vector induced immunity upon use as a 
therapeutic agent can prevent its use in the same person more 
than once. Therefore, we discuss the effect of innate and 
adaptive immune responses against human and non-human 
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Evading Neutralizing Antibodies and Immune Responses 
  Upon primary exposure to Ads, an immunocompetent 
host will generate innate immune responses within hours of 
infection and robust adaptive responses are generated over 
the course of two weeks. Therefore, Ad vector administra-
tion in the naïve host produces transgene expression that 
generally peaks within days of injection after which expres-
sion is eliminated within two weeks due to CTL responses 
against Ad, Ad-infected cells, and/or transgene epitopes 
[130].  
  Upon secondary exposure to an Ad serotype, memory T 
cells expand a population of CTL effector cells more rapidly 
than in the first exposure to swiftly eliminate Ad-transduced 
cells. Furthermore, capsid-directed antibodies can neutralize 
a large fraction of virions to drastically blunt the level of 
transgene expression that would normally occur. The degree 
of neutralization can depend on the site of administration. 
Intravenous injection of Ad exposes it to large concentra-
tions of systemic antibodies that efficiently decrease trans-
duction [131]. In contrast, if the virus is injected at surfaces 
with lower levels of persistent antibodies (i.e. nasally, orally, 
vaginally), the systemically-immune host may not neutralize 
the virus effectively [132]. Similarly, injection into an iso-
lated tissue (i.e. a tumor) or into an immunologically-
privileged site (i.e. the eye) can prevent or reduce antibody 
neutralization.  
  The ability to cross-neutralize another Ad is directly de-
pendent on the ability of the polyclonal Ad antibodies to 
bind to conserved epitopes on the Ad surface. For example, 
neutralizing antibodies generated against Ad5 are most effec-
tive at neutralizing Ad5, but can also partially neutralize Ads 
of the same species. T cell responses can be more broadly 
cross-reactive, since functional protein structures are less 
variable. For example, amino acids involved with hexon 
trimer structure and interactions with other capsomer pro-
teins are conserved even between Ad species and are good 
targets for major histocompatibility complex (MHC) class I 
and class II. On the other hand, HVRs on hexon are not in-
trinsic to function and widely vary to evade other serotypes’ 
neutralizing antibodies.  
  As the most abundant capsid protein, most neutralizing 
antibodies are directed at hexon. Hexon-targeted antibodies 
appear to neutralize the virus not by blocking viral entry but 
instead by blocking microtubule transport of the virus to the 
nucleus after it escapes endosomes [133]. The second most 
prevalent neutralizing antibodies are against Ad fiber [54, 
134]. These can block interactions with receptors or by tar-
geting the virus to antigen-presenting cells [135]. Immune 
system targeting of these two proteins is also reflected Ad 
fiber and hexon protein diversity since a comparison of Ad 
serotypes shows that hexon and fiber are most variable even 
within one species of the virus [13, 37]. 
  Multiple studies have shown that most humans are im-
mune to Ad5, although levels of immunity are geographi-
cally variable and differences in testing for neutralization 
does not lend itself to ideal comparison. According to some 
estimates, 30-50% of Americans, 60% of Japanese, and 45-
75% of people from Europe (Italy, UK, Netherlands, and 
Belgium) have pre-existing immunity to Ad5 [136, 137]. 
Ad5 seroprevalence can even reach as high as 100% of peo-
ple in regions such as Brazil, sub-Saharan Africa and India 
[22, 138-140].  
  Ad seroprevalence within populations is strongly corre-
lated with increasing age, presumably as a result of natural 
infections [139, 141]. One exception is infants below the age 
of 6 months, who can receive passive but transient immunity 
against Ad5 through maternally derived antibodies [139]. 
This seroprevalence data presents a clear “window” of low 
anti-Ad immunity in children between the age of 6 months 
and 7 years, and may signify the ideal time for Ad based 
therapies.  
  Delivery of an Ad in a pre-immune host may not only 
attenuate therapy, but also have unexpected effects. A recent 
example is the now infamous Merck STEP HIV Vaccine 
trial. In this Phase II clinical trial, first generation (FG) E1-
deleted Ad5 vaccines expressing gag, pol, and nef were used 
in individuals at high risk of HIV-1 infection as a T cell gen-
erating HIV vaccine strategy [142]. While this trial showed 
some positive immunologic effects, it was halted after failing 
to decrease HIV infection. Unexpectedly, early data from the 
STEP trial suggested that uncircumcised individuals with 
higher titers of pre-existing antibodies against Ad5 also had 
higher rates of HIV acquisition than volunteers with low Ad5 
antibodies [142-144]. Based on this, Ad5-based vaccines fell 
out of favor [145-147].  
  Tests to understand STEP trial effect suggested that prior 
immunity to Ad5 followed by exposure to Ad5 could induce 
stimulate a population of CD4+ T cells that might become 
substrate for HIV infection [148]. However, further investi-
gation has failed to demonstrate any true correlation between 
pre-existing immunity and likelihood of HIV infection [140, 
149, 150]. Follow up of STEP vaccinees shows that there is 
no longer a statistical difference in HIV acquisition between 
groups with high or low antibodies vs. Ad [142]. Prior im-
munity to Ad5 in a parallel Ad5 trial called the Phambili trial 
had no effect on HIV acquisition [142]. Finally, a recent case 
control study shows that immunity to Ad5 does not pose 
increased risk of HIV infection [140].  
  Therefore, it is now unclear if the STEP trial effect was 
real or was a transient effect. Other Ad vaccines, such as the 
live attenuated Ad4 and Ad7 vaccines for military recruits 
are considered so safe that they are again in production as 
replication-competent vaccines [151]. 
Adenovirus Serotype-switching to Evade the Immune 
System 
  One approach to evade neutralizing antibodies is to “se-
rotype switch” the vector by changing the Ad serotype carry-
ing genes with each administration [152]. This approach 
markedly increases prime-boost with Ad vaccines as demon-
strated for HIV vaccines [21, 153-155]. Because of their low 
cross-reactivity and seroprevalence in humans, chimpanzee 
adenoviruses Ad-C68, 6, and 7 have been studied for vaccine 
purposes. Ad-C68 was shown to be effective at inducing 
anti-rabies neutralizing antibodies and may be capable of 
inducing anti-HIV-1 gag CTL immune responses [21, 156]. 
Santra  et al. confirmed that simian Ads C7, C68 and chi-
meric C1/C5 were capable of inducing immune responses in 
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prime/boost immunization strategies [157]. In addition to 
their use as vaccine vectors a simian adenovirus ChAd3 was 
shown to be effective at expressing carcinoembryonic anti-
gen (CEA) and was as robust as huAd5 at breaking tolerance 
and successfully overcoming tumorigenicity in the presence 
of huAd5 pre-existing immunity [158]. 
 Liu  et al. explored the use of a recombinant human sero-
type 26 adenovirus as a vector for a T-cell based anti-SIV 
vaccine. A further advantage of Ad26 was that it was only 
found to have a 21% level of seroprevalence in Sub-Saharan 
Africa, a region in desperate need of an HIV-1 vaccine [22]. 
Using a heterologous prime/boost of Ad26 and Ad5 express-
ing SIV gag they were able to show a 1.4 and 2.4 log reduc-
tion in peak and chronic viremia levels, respectively [159]. 
Ad48 was found to have a seroprevalence of only 3% in the 
same region [22]. In another study, the hexon hypervariable 
regions (HVRs) of Ad5 were replaced with the HVRs of 
Ad48 hexon. This new Ad5HVR48 virus expressed SIV 
Gag, Pol, Nef and Env and immunized macaques were found 
to have lower peak and setpoint viremia levels [160].  
  The vast majority of work with adenovirus vectors has 
utilized first generation Ad (FG-Ad) vectors that are typi-
cally deleted for their E1 and E3 genes (see [12]). FG-Ad 
vectors carry 17 Ad protein open reading frames (ORFs) that 
can be expressed and targeted by anti-Ad T cell responses 
[161, 162]. In contrast, in helper-dependent adenoviral (HD-
Ad) vectors, all viral ORFs are deleted [163-165]. No Ad 
proteins are produced in HD-Ad vector-transduced cells 
thereby evading T cells responses that can kill transduced 
cells [163-165]. This reduced immunogenicity and reduced 
liver damage allows for transgene expression in mice and in 
baboons over years [8, 166-168]. The HD-Ad system is also 
uniquely suited to serotype switching, since Ads of the spe-
cies can cross-package each other’s genomes. HD-Ads there-
fore give the opportunity to evade both anti-Ad T cell re-
sponses and Ad neutralizing antibodies. Their low immuno-
genicity not only increases their safety, but also increases 
their persistence in vivo. We recently studied the utility of 
serotype switching HA-Ads 1, 2, 5 and 6 that expressed HIV 
Env gp140 [23] to show that serotype switching in both mice 
and rhesus macaques boosted anti-HIV immune responses. A 
subsequent challenge of the HD-Ad serotype switch immu-
nized macaques resulted in impressive immune control of 
viremia in SHIV-SF162P3 challenged animals with 2 – 10 
fold decreases in peak viremia with set-point viremia levels 
~4 logs lower [169]. 
Polymer Modification of Ads to Evade Immune Re-
sponses 
  An original attraction of polymers like PEG for Ad coat-
ing was to protect it from neutralizing antibodies [98, 101, 
102]. When tested in mouse models, PEG and HPMA poly-
mers are able to protect Ad from pre-existing and vector-
induced neutralizing antibodies to allow multiple administra-
tions into immune recipients [93, 98, 101, 102]. Ad PEGyla-
tion also reduces the production of new antibody and cellular 
immune responses against Ad proteins [101].  
  While PEGylation does cover the virus with as many as 
15,000 PEGs, it does not completely shield the virus and 
PEGylated vectors recover only 10% of normal vaccine ac-
tivity in the face of anti-Ad antibodies ([93] and data not 
shown). In addition, the negative effects of random PEGyla-
tion on virus transduction can mitigate the benefits of anti-
body shielding. For example, when we tested succinimide-
activated NHS-PEG for gene-based vaccination with Ad, this 
random PEGylation ablates CAR-mediated transduction in 
vitro and reduces in vivo transduction after intramuscular 
(i.m.) and intranasal (i.n.) vaccination by 50 to 90% [93]. 
This loss of activity by i.m. and i.n. routes differs markedly 
with the retention of in vivo transduction after i.v. injection 
[70, 88, 107]. This difference is likely due to loss of needed 
CAR binding by i.m. and i.n. transduction as compared to 
FX-mediated transduction after i.v. injection.  
  One possible solution to this conundrum is the use of 
targeted PEGylation of Ad [95, 105, 106, 114]. These tar-
geted PEG vectors not only retain full in vitro transduction, 
but targeted PEGylation of Ad at HVR1, 2, 5, and 7 actually 
increases transduction after i.v. injection up to 20-fold [95]. 
To what degree polymer modification will protect viruses 
from antibodies in vivo remains to be demonstrated in prime-
boost systems. 
  While there is some question of exactly how well poly-
mers can protect virus from neutralizing antibodies, there is 
good evidence showing that PEGylation can blunt many of 
the innate immune responses against Ad [70, 170-172]. 
When injected i.v. into mice, PEGylation reduced innate 
immune responses as evidenced by a 90% reduction in IL-6 
over 48 hours [70] and IL-12 and TNF-alpha levels were 
reduced three- and seven-fold, respectively [170]. In ba-
boons, PEGylation reduced IL-6 3-fold, IL-12 by 50% [172]. 
Notably, PEGylation of Ad also reduces uptake of the virus 
into antigen-presenting cells including macrophages and 
Kupffer cells [70]. It also inhibits complement activation by 
Ad5 [58].  
ADENOVIRAL VECTOR RETARGETING  
  A better understanding of the sinks that absorb adenovi-
ruses is crucial to retargeting these vectors to novel receptors 
and increasing its therapeutic success. Our earlier review and 
several others have discussed a number of strategies for vec-
tor retargeting which is crucial for both targeted gene therapy 
and oncolytic purposes [12, 173-175]. Below, we highlight 
new areas of Ad retargeting approaches that have been ap-
plied since the last review. 
Peptide Inserts/Ligands/Linkers 
  The selection of targeting peptides from phage libraries 
and their insertion into the viral capsid has been reviewed in 
previously [12, 176]. These methods were unpredictable with 
regard to whether peptide insertions would be tolerated by 
the virus and retain their specificity. One approach to cir-
cumvent these problems involved selecting peptides from a 
bacteriophage library that displayed random peptides in the 
context of the Ad fiber HI loop, into which it would later be 
cloned [177]. More recently, Ad peptide libraries have been 
created in which random peptides are cloned directly into the 
Ad capsid. In this way, functional virions can be directly 
selected [178-180]. This technique was modified to accom-
modate the insertion of peptides with known affinity for cel-
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that had a constant binding peptide insert flanked with ran-
dom linker sequences [179]. Virions could then be selected 
for functional virus with retained binding specificity [181]. 
Although these Ad libraries could theoretically contain up to 
10
9 unique peptides, current techniques to produce actual Ad 
virions have only yielded library sizes of up to 2 x 10
5 [178, 
179]. This imposes a significant restriction of the size of 
peptides that can be screened as ligands. For example, a 10
5 
peptide library in Ad can represent only four amino acid-
long random peptides. In contrast, a 10
10 peptide library on 
bacteriophage can represent seven amino acid peptides (re-
viewed in [176]). 
  The success of peptide insertions for targeting is not only 
dependent on the peptides, but also on their location on the 
capsid. Ad peptide libraries are currently limited to fiber 
insertions. The generation of pIX or hexon based Ad peptide 
libraries may yield viruses that can take advantage of low 
affinity, high avidity interactions. The recent high resolution 
x-ray crystal and cryo-EM based structures of adenovirus 
may provide new insight into other regions of the virus that 
may tolerate modification for targeting [182-184].  
  Targeting adenovirus through the incorporation of high 
affinity proteins like antibodies has been hampered by both 
the large size of antibodies and improper folding of antibod-
ies in the reducing environment of the nucleus where Ad is 
assembled. To circumvent this incompatibility, molecular 
adapters have been designed to bind to the Ad capsid outside 
of the context of the nucleus. The first such adapter consisted 
of a soluble form of CAR (sCAR) fused to targeting mole-
cules like FGF-2, EGF [185], carcinoembryonic antigen 
(CEA)[186, 187], and folate [188, 189]. More recently, an-
other targeting adapter molecule consisting of the GLA do-
main from FX fused to single-chain antibodies was devel-
oped [190]. The FX fusion protein binds to hexon, and there-
fore has 240 binding sites as opposed to the 12 available 
fiber proteins available to sCAR on the viral capsid. By bind-
ing to the HVR of hexon, native FX binding is reduced and 
enables detargeting from the liver. Another possible benefit 
of this technique is that it may allow improved spread of 
virus in an oncolytic setting since targeting is not affected by 
excess fiber production [190]. A major hurdle to this target-
ing method is that the adaptor molecules rely on non-
covalent protein-protein interactions for their conjugation to 
the Ad capsid, which are generally considered too weak in 
vivo. Naturally occurring antibodies or CAR receptors could 
compete for Ad binding and displace the molecular adaptors 
from the capsid, abolishing the vector targeting activity. 
  In a third adapter molecule strategy, ankyrin repeat pro-
teins (DARPins) have been designed to bind to fiber with 
low nanomolar affinity [191-193]. DARPins are cysteine-
less alternatives to antibodies that consist of helical repeats 
containing protein interaction surfaces. A DARPin library 
was created and used to select DARPins specific for both 
fiber and the target protein HER2. Fusion molecules of fi-
ber/HER2 binding DARPins can be produced in E. coli and 
have been used to target adenovirus to HER2 positive cells. 
Further study will be needed to determine if these adapter 
proteins will have any utility in vivo [194].  
 
SUMMARY 
  As research in Ad biology progresses, we begin to appre-
ciate that vector pharmacology is less reliant on direct recep-
tor binding and more influenced by complex interactions 
between virus and host. Ad engineering efforts have gener-
ally been concerned with targeting vectors to an intended 
location, and recent research demonstrates the paradigm shift 
from fiber to hexon modification. In vivo, the interactions of 
hexon and blood factors can be harnessed for liver-directed 
gene therapy. Conversely, this same interaction can be a con-
siderable viral sink for the purposes of therapy beyond the 
liver.  
  Our growing understanding of Ad biology suggests that 
Ad encounters progressive viral sinks in addition to blood 
factors, such as interactions with circulating cells, antibodies, 
and complement. More formidably, organs like the liver trap 
enormous doses of therapeutic vector particles, yet even this 
sequestration is partitioned into regions such as hepatocytes, 
Kupffer, and endothelial cells. Here we summarize not only 
the obstacles Ads face in vivo, but also strategies that have 
been used to evade them. It has become clear that direct tar-
geting strategies may have significantly increased success 
when detargeting strategies are applied in combination. 
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